SCHEMBL6251433

SCHEMBL6251433

CC(=O)c1ccc(NC=S)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.53
NPC1 O15118 6/20 0.53
MAPT P10636 5/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
KDM4E B2RXH2 1/20 0.53
TAAR1 Q96RJ0 1/20 0.48
KMT2A Q03164 2/20 0.47
HTT P42858 2/20 0.47
MEN1 O00255 1/20 0.47
NLRP1 Q9C000 1/20 0.47
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA9 Q16790 2/20 0.46
CYP1A1 P04798 1/20 0.46
CYP1B1 Q16678 1/20 0.46
HPGD P15428 3/20 0.43
LMNA P02545 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1555352 0.81 MAPT (0.54) RAB9ANPC1MAPTSMN1; SMN2KDM4E
SCHEMBL10601664 0.81 MAPT (0.54) RAB9ANPC1MAPTSMN1; SMN2KDM4E
SCHEMBL8764231 0.76 ALDH1A1 (0.35) ALDH1A1
SCHEMBL29043036 0.75 MAPT (0.57) RAB9ANPC1MAPTSMN1; SMN2TAAR1
SCHEMBL6906973 0.75 RAB9A (0.60) RAB9ANPC1MAPTSMN1; SMN2TAAR1
SCHEMBL10467423 0.75 MAPT (0.56) RAB9ANPC1MAPTSMN1; SMN2KDM4E
SCHEMBL13183754 0.75 MAPT (0.49) RAB9ANPC1MAPTSMN1; SMN2KDM4E
SCHEMBL50646 0.74 MAPT (0.68) RAB9ANPC1MAPTSMN1; SMN2KDM4E
SCHEMBL3339435 0.73 CYP1A1 (0.53) RAB9ANPC1MAPTSMN1; SMN2KDM4E
SCHEMBL3339432 0.73 CYP1A1 (0.53) RAB9ANPC1MAPTSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2005530823-A 2005-10-13 JP claimed
US-20050215553-A1 Hexahydropyridazine-3-carboxylic acid hydrazide and hydrazone derivatives, combinatorial libraries containing same, pharmaceutical compositions containing same and methods of preparation AVENTIS PHARMA S.A. (FR) 2005-09-29 US claimed
EP-1515953-A2 NOVEL HEXAHYDRO-PYRIDAZINE-3-CARBOCYLIC ACID HYDRAZIDE OR HYDRAZONE DERIVATIVES, COMBINATORIAL LIBRARIES CONTAINING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS FOR PREPARING SAME Aventis Pharma S.A. (FR) 2005-03-23 EP claimed
WO-2003106431-A2 NOVEL HEXAHYDRO-PYRIDAZINE-3-CARBOCYLIC ACID HYDRAZIDE OR HYDRAZONE DERIVATIVES, COMBINATORIAL LIBRARIES CONTAINING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS FOR PREPARING SAME AVENTIS PHARMA S.A. (FR) 2003-12-24 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215553-A1 Hexahydropyridazine-3-carboxylic acid hydrazide and hydrazone derivatives, combinatorial libraries containing same, pharmaceutical compositions containing same and methods of preparation HK1, ACE, CTSZ RAB9A 2772/4885NPC1 2836/4885MAPT 3235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.